Series C - Zenas BioPharma
Investment Firm
Overview
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.
Announced Date
May 07, 2024
Closed on Date
May 07, 2024
Funding Type
Series C
Highlights
Location
United States, North America
Social
Investor Lead
Norwest Venture Partners
Norwest Venture Partners is a convertible_note and debt and early_stage_venture and late_stage_venture and private_equity and secondary_market and venture firm.
New Enterprise Associates
New Enterprise Associates is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and venture firm.
SR One
SR One is a early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.
Delos Capital
Delos Capital is a debt and early_stage_venture and late_stage_venture and post_ipo and private_equity firm.
Participant Investors
13
Round Details and Background
Zenas BioPharma raised $200000000 on 2024-05-07 in Series C
Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.
Company Funding History
3
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Nov 07, 2022 |  Series B - Zenas BioPharma | 13 | - | 118.0M |
| Mar 23, 2021 | Series A - Zenas BioPharma | 5 | - | undefined |
| May 07, 2024 | Series C - Zenas BioPharma | 15 | - | 200.0M |
Recent Activity
There is no recent news or activity for this profile.